/
AKBA
$1.11-$0.03 (-2.63%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$305.8M
268M shares
52-week range
$0.82 – $4.08
9% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.68
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $207.7M | $335.0M | $294.6M | $211.7M | $292.5M | $194.6M | $160.2M | $236.2M |
| Cost of revenue | $7.7M | $145.3M | $64.0M | $81.5M | $22.5M | $74.1M | $63.2M | $39.5M |
| Gross profit | $200.1M | $189.7M | $230.7M | $130.2M | $270.0M | $120.5M | $97.0M | $196.7M |
| Gross margin | 96.3% | 56.6% | 78.3% | 61.5% | 92.3% | 61.9% | 60.6% | 83.3% |
| R&D | $291.1M | $323.0M | $218.5M | $147.9M | $166.0M | $63.1M | $37.7M | $62.4M |
| Operating income | −$178.1M | −$286.3M | −$377.8M | −$264.5M | −$80.8M | −$46.3M | −$50.5M | $23.5M |
| EBITDA | −$178.1M | −$249.9M | −$139.8M | −$189.9M | $3.1M | −$8.3M | −$13.7M | $21.7M |
| Net income | −$171.9M | −$279.7M | −$384.8M | −$282.0M | −$94.2M | −$51.9M | −$69.4M | −$5.3M |
| Net margin | -82.7% | -83.5% | -130.6% | -133.3% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (diluted) | -1.47 | -2.36 | -2.53 | -1.48 | -0.58 | -0.28 | -0.33 | -0.02 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $207M | $-0.14 | $-0.17–$-0.10 | 3 |
| 2027 | $160M | $-0.23 | $-0.25–$-0.22 | 3 |
| 2028 | $202M | $-0.10 | $-0.20–$0.02 | 4 |
| 2029 | $221M | $-0.05 | $-0.05–$-0.04 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Akebia Therapeutics, Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
www.akebia.com- Employees
- 194
- IPO / List date
- Mar 20, 2014
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds AKBA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,833,128 | $2.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AKBA yet.
